Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Knight Therapeutics's change in inventory for the quarter that ended in Mar. 2026 was C$-3.3 Mil. It means Knight Therapeutics's inventory
increased by C$3.3 Mil
from Dec. 2025 to Mar. 2026 .
Knight Therapeutics's change in inventory for the fiscal year that ended in Dec. 2025 was C$-17.8 Mil. It means Knight Therapeutics's inventory
increased by C$17.8 Mil
from Dec. 2024 to Dec. 2025 .
Days Inventory indicates the number of days of goods in sales that a company has in the inventory.
Knight Therapeutics's Days Inventory for the quarter that ended in Mar. 2026 was 159.76.
Inventory Turnover measures how fast the company turns over its inventory within a year.
Knight Therapeutics's Inventory Turnover for the quarter that ended in Mar. 2026 was 0.57.
Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue.
Knight Therapeutics's Inventory-to-Revenue for the quarter that ended in Mar. 2026 was 0.94.
3. Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue.
Knight Therapeutics's Inventory to Revenue for the quarter that ended in Mar. 2026 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Knight Therapeutics Change In Inventory Related Terms
Knight Therapeutics Change In Inventory Historical Data
* Premium members only.
The historical data trend for Knight Therapeutics's Change In Inventory can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Knight Therapeutics Change In Inventory Calculation
Change In Inventory is the difference between last period's ending inventory and the current period's ending inventory.
Change In Inventory for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was C$18.1 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
What does a Change In Inventory of C$18.1 Mil mean?
Knight Therapeutics (TSX:GUD) has a Change In Inventory of C$18.1 Mil as of Mar. 2026. Change in Inventory is the difference between current-period inventory and past-period inventory. View historical data for Knight Therapeutics and its competitors.
Is Knight Therapeutics' Change In Inventory too high?
Knight Therapeutics' current Change In Inventory is C$18.1 Mil. Overall, Knight Therapeutics has a GF Score™ of 72/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Knight Therapeutics' Change In Inventory compare to ZTS?
Knight Therapeutics' Change In Inventory of C$18.1 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Change In Inventory for a Drug Manufacturers company?
A good Change In Inventory depends on the Drug Manufacturers industry context. However, Change In Inventory should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Change In Inventory mean?
A high Change In Inventory can signal that a stock is expensive relative to its fundamentals. Change in Inventory is the difference between current-period inventory and past-period inventory. View historical data for Knight Therapeutics and its competitors. Knight Therapeutics's current Change In Inventory is C$18.1 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Knight Therapeutics stock overvalued right now?
Based on GuruFocus' analysis, Knight Therapeutics (TSX:GUD) is currently considered Modestly Overvalued. The stock's GF Value™ is C$8.66, compared to a current price of C$9.84 — trading 13.6% above its estimated fair value. The current Change In Inventory is C$18.1 Mil. Knight Therapeutics' overall GF Score™ is 72/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Change In Inventory calculated?
Change In Inventory is calculated from a company's financial statements. For Knight Therapeutics (TSX:GUD), the current Change In Inventory is C$18.1 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Knight Therapeutics (TSX:GUD) Overvalued in 2026?
Based on GuruFocus' analysis, Knight Therapeutics stock appears to be overvalued.
The current stock price of C$9.84 is trading 13.6% above its estimated GF Value™ of C$8.66.
GuruFocus considers Knight Therapeutics to be Modestly Overvalued.
Key valuation signals for TSX:GUD:
Change In Inventory: C$18.1 Mil
GF Value™: C$8.66 vs. price of C$9.84 (13.6% above fair value)
No single metric tells the full story. See the TSX:GUD stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Knight Therapeutics Inc is a specialty and generic drug manufacturing company. The company's principal business activity is focused on developing, acquiring, in-licensing, out-licensing, marketing, and commercializing pharmaceuticalproducts. and distributing pharmaceutical products, consumer health products, and medical devices in Canada, Latin America and select international markets. The company finances other life sciences companies across the globe in order to generate interest income, strengthen relationships in the life sciences industry, and to secure product distribution rights. Geographically, the company generates revenue from Brazil, Canada, Colombia, Argentina, Mexico, Rest of LATAM, and Others, with the majority revenue generated from the Brazil region.
72GF Score
Get the complete analysis for TSX:GUD
Change In Inventory is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
TSX:GUD has been successfully added to your 
